Jasra Sakshi, Kazemi Mohammed, Shah Nishi, Chen Jiahao, Fehn Karen, Wang Yanhua, Mantzaris Ioannis, Kornblum Noah, Sica Alejandro, Bachier LizaMarie, Goldfinger Mendel, Gritsman Kira, Braunschweig Ira, Steidl Ulrich, Shastri Aditi, Verma Amit
Department of Hematology/Oncology, University of Vermont, 89 Beaumont Avenue, Given E-214, Burlington, VT, 05405, USA.
Albert Einstein College of Medicine, Department of Hematology/Oncology, Bronx, NY, USA.
Exp Hematol Oncol. 2021 Jan 4;10(1):1. doi: 10.1186/s40164-020-00186-y.
Optimal treatment of acute myeloid leukemia (AML) arising in elderly patients remains a challenge. FDA approval of Ivosidenib and Enasidenib, small molecule inhibitors of isocitrate dehydrogenase enzymes (IDH1 and 2) have opened new avenues of treatment. We present a 60-year-old woman with refractory AML, achieving complete response to the combination therapy of hypomethylating agent, Azacytidine with the IDH2 inhibitor, Enasidenib, and BCL2 inhibitor, Venetoclax. To our knowledge, this is the first case report of a patient with IDH2 mutated refractory AML achieving complete response to combination therapy with azacytidine, enasidenib and venetoclax.
老年患者急性髓系白血病（AML）的最佳治疗仍然是一项挑战。美国食品药品监督管理局（FDA）批准的异柠檬酸脱氢酶（IDH1和2）小分子抑制剂艾伏尼布和恩杂鲁胺开辟了新的治疗途径。我们报告了一名60岁的难治性AML女性患者，其对去甲基化药物阿扎胞苷与IDH2抑制剂恩杂鲁胺以及BCL2抑制剂维奈克拉的联合治疗实现了完全缓解。据我们所知，这是首例IDH2突变的难治性AML患者对阿扎胞苷、恩杂鲁胺和维奈克拉联合治疗实现完全缓解的病例报告。
